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In recent years, we have witnessed a signiﬁcant increase in the amount of studies using Mesenchymal
Stem Cells (MSCs) for cancer therapy, mostly as vectors for drug or gene delivery strategies. This is
because of their intrinsic capacity of homing into tumor niches. However, the interactions between MSCs
themselves and tumor cells is not fully understood, with contradictory results frequently being observed
regarding their effects on cancer cell invasion and proliferation. This poses an important question of
safety in respect to the application of these cells. The source of the MSC population used, as well as the
type of cancer cells under study might strongly inﬂuence this interaction. Moreover, differences in
isolation protocols, culture media compositions, time of culture and conditioned media collection, or
even timing and mode of MSCs administration to in vivo models of cancer may also affect the interaction
MSC-tumor cells. In this review, we drive our focus into malignant brain tumors, particularly gliomas,
one of the deadliest forms of cancer. Moreover, we look with some detail into different studies using
MSCs as a treatment for brain tumors and compare them, highlighting the main deviations and simi-
larities among them.
© 2018 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights
reserved.1. Introduction
Malignant gliomas are the most common primary brain tumor
(representing 80% of all malignant brain tumors) and one of the
deadliest forms of cancer [1]. It is believed that they have a glial
origin or derive from stem/progenitor cells that undergo malignant
transformation [2]. Glioma mainly develops in the brain, although
it can also develop in other parts of the CNS. Glioblastoma (GBM) is
the most common and aggressive subtype of glioma. Current
treatment techniques are based on tumor resection followed by
sessions of radio and/or chemotherapy. However, despite all the
efforts developed in the last decades, patients' prognosis has only
increased a few months [3]. One of the reasons for the high mor-
tality rates registered and for the difﬁculties found in treating GBMd Health Sciences Research
ho, Campus de Gualtar, 4710-
gado).
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iochi.2018.07.008is the tumor's inﬁltrative capacity. The tumor cells possess a high
proliferative and invasive proﬁle, which makes complete surgical
resection virtually impossible and increases the probability of tu-
mor recurrence. Recent evidences suggest that remarkable tumor
heterogeneity, and poor response to current therapies are also
partly due to the existence of cancer stem cells (CSCs). Similar to
other stem cells, CSCs have a self-renewal capacity and can differ-
entiate into different cell phenotypes, originating the main cell
populations forming the tumor [4].
The development of new therapeutic options, capable of tar-
geting not only the “bulk” tumor cells but also CSCs, remains
therefore an important need.
The application of Mesenchymal Stem Cells (MSCs) in different
therapeutic approaches is becoming common in recent years. The
identiﬁcation of these cells is credited to the work of Friedenstein
and colleagues in the 1960s [5], where they observed that a subtype
of cells isolated from the iliac crest's bone marrow were plastic
adherent and could differentiate into chondrocytes and osteoblasts.
Nowadays, MSCs are deﬁned according to three main characteris-
tics: 1) their ability to adhere to plastic surfaces; 2) the expression
of markers like CD105, CD73 and CD90 and the lack of expression ofaire (SFBBM). All rights reserved.
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their differentiation potential into osteoblasts, chondrocytes and
adipocytes (multipotency potential) [6]. In addition, MSCs are also
characterized by their proliferative capacity and self-renewal abil-
ity. Moreover, MSCs and their secretome exhibit trophic properties
that promote regeneration in lesioned tissues [7]. This could be due
to a modulation of the inﬂammatory responses [8] and induction of
angiogenesis [9], enhancing the endogenous regeneration process.
These properties associated with their differentiation potential led
to the application of MSCs as a component of engineered tissue
constructs, replacing diseased or damaged tissues [10].
MSCs have been mainly obtained from the bone marrow (BM-
MSCs) [11]. However, they can also be isolated from the adipose
tissue (ASCs) [12,13], the umbilical cord [either umbilical cord itself
(UC-MSCs) or its blood (UCB-MSCs)] [14] and more recently from
skeletal muscles [15], dental tissues [16], synovial ﬂuid [17], pala-
tine tonsil [18], parathyroid gland [19], fallopian tube [20], brain
[21], placental [22,23], endometrial tissues [24] and uterine cervix
[25,26].
Despite the wide range of therapeutic uses for MSCs, their
application to cancer treatment remains controversial. Some
studies show that factors produced by MSCs can inhibit tumor
growth in different animal models (including gliomas) [27,28],
while others state that their use should be further investigated as
they could instead promote characteristics of tumor malignancy
[29]. Regarding recently-found sources of MSCs, conditioned media
(CM) obtained from heat-treated amniotic ﬂuid-derived MSCs
showed a suppressive effect on ovarian tumor progression and
malignancy [30]. Bu and colleagues demonstrated that human
endometrial MSCs derived from menstrual blood present anti-
tumor properties against epithelial ovarian cancer in vitro and
in vivo [31]. In a very interesting work, Eiro et al. applied CM of
MSCs from human uterine cervix (hUCESC) to breast cancer cell
lines and primary tumors, inducing a reduction in cell proliferation
and invasion, alterations in cell cycle and increased apoptosis [25].
The collected CM also affected cancer-associated ﬁbroblasts,
reverted macrophage differentiation and when applied into a
xenograft mouse tumor model, reduced tumor growth and
increased overall survival [25]. Nevertheless, a relevant ﬁnding
about MSCs is their homing ability to tumors. This has been
demonstrated in several studies and opens a door for targeted
therapies.
2. MSCs tropism towards tumors
The tropism of MSCs towards established gliomas has already
been shown by Nakamizo and colleagues in 2005 [32]. Human BM-
MSCswere injected into the carotid arteries of mice andwere found
exclusively within brain tumors, which did not happen with
injected ﬁbroblasts or U87 glioma cells that presented a more
widespread distribution. In addition, BM-MSCs intracranially
injected into the opposite side of the tumor were capable of
migrating into the xenograft. The authors also demonstrated that
CM from gliomas speciﬁcally supported BM-MSCs’ invasion in an
in vitro Matrigel assay, and that platelet-derived growth factor
(PDGF), epidermal growth factor (EGF) and stromal cell-derived
factor-1a (SDF-1a) were partially responsible for the enhanced
MSCs invasion.
In the same direction, glioma cells engineered to secrete high
levels of PDGF-BB attracted more human MSCs than low secreting
gliomas [33]. Moreover, neutralizing this protein or its receptor
(PDGFR-B) reduced themigratory capacity of MSCs. Similar ﬁndings
were obtained in vivo, highlighting a relevant role of PDGF signaling
in this innate tropism of MSCs to glioma cells. After exploring more
this mechanism, Hu et al. (2013) proposed a role for vascular cellPlease cite this article in press as: E.D. Gomes, et al., The impact of Mese
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VCAM-1 neutralization inhibited BM-MSCs migration [34]. More
recently, it was shown that stimulation with PDGF-BB led to an
increased VCAM-1 expression by MSCs. CD44 expression was also
augmented in BM-MSCs following PDGF-BB 12 h treatment [35].
Moreover, antibody neutralizing experiments resulted in inhibited
migratory ability, as well.
Interleukin 8 (IL8) produced by glioma cell lines was demon-
strated to be a chemoattractant to human UCB-MSCs, which had
higher expression of IL8 receptors CXC chemokine receptors 1 and 2
(CXCR1 and CXCR2), in comparison to BM-MSCs that presented less
migratory ability towards glioma [36]. Overexpression of CXCR1
further augmented the migration capacity of UCB-MSCs [37]. In a
different study, rat BM-MSCs were shown to express CXCR4, be-
sides CCR2, the respective receptors for MCP-1 and the above-
mentioned SDF-1a [38]. These two factors were shown to be
important for MSCs migration in this and other studies [39].
Overexpression of CXCR4 in human UCB-MSCs also resulted in
enhanced MSCs migratory capacity [40].
Other factors that might be responsible for the attraction of
MSCs to gliomas include vascular endothelial growth factor (VEGF)
[41], hepatocyte growth factor (HGF) [42], transforming growth
factor b1 (TGF-b1) [43] and neurotrophin 3 (NT-3) [44].
In what regards MSCs, those that express matrix metal-
loproteinase 1 (MMP1) at higher levels presented an increased
migratory capacity [45]. Blocking the interaction between MMP1
and the protease-activated receptor 1 (PAR1) diminished MSCs
migration properties. Upregulation of lymphocyte adhesion mole-
cule (ALCAM) and N-cadherin also seems to be relevant for MSCs
homing ability [46]. Additionally, the suppressor gene p27 was
associated toMSCsmigration towards tumors [47]. MSCs from p27-
null mice had decreased motility in vitro and in vivo in a C6 glioma
model.
Interestingly, the tropism of MSCs towards gliomas seems to be
augmented by ionizing radiation (IR) [48], with the C-C motif
chemokine 2 (CCL2), present in glioma cells' secretome, playing an
important role in this mechanism. This is another important aspect
to consider when transplanting MSCs, which is conjugating cell-
based therapy with other more conventional cancer therapies. A
schematic representation of the different mechanisms proposed for
MSCs tropism towards gliomas can be found in Fig. 1.
Taking into account this capacity of MSCs to migrate towards
tumors, these cells have been extensively used to deliver drugs or
gene therapy to gliomas. Some of these have shown important
beneﬁts in animal models of glioma and are reviewed by Stuckey
and Shah (2014) [49].
MSCs engineered to express and secrete cytokines such as IL2
[28], IL12 [50], IL18 [51] or interferon b (IFN-b) [52], suicide gene
therapy based on cytosine deaminase (CD) [53] or herpes simplex
virus thymidine kinase (HSV-tk) [54], nanoparticles [55], or tumor
necrosis factor-related apoptosis inducing ligand (TRAIL) [56], are
just some examples, with interesting results regarding tumor
treatment, mainly in in vivo pre-clinical models.
Despite this promising data, the interaction between the “naïve”
MSCs and tumor cells remains elusive.
3. MSCs interaction with tumors
One of the ﬁrst works studying the interaction between MSCs
and tumors was performed by Djouad et al., in 2003 [57]. The in-
jection of B16 melanoma cells in mice led to tumor formation only
when MSCs (from murine origin) were co-injected. At the time, it
was proposed that the immunosuppressive properties of MSCs
were responsible for this effect, resulting in a more pro-
tumorigenic environment [57].nchymal Stem Cells and their secretome as a treatment for gliomas,
Fig. 1. Some of the molecular mechanisms involved in Mesenchymal Stem Cells (MSCs) tropism towards Glioma cells. Most of the mechanisms are based on the secretion of
chemoattractant molecules by glioma cells and their interactions with different receptors/membrane proteins present in MSCs.
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of glioma was performed by Nakamura and colleagues [28]. Here,
the authors demonstrated that MSCs derived from the bone
marrow of rats could migrate toward syngeneic rat brain tumors
(9 L glioma cell line) via the corpus callosum, after intracranial in-
jection of theMSCs into the contralateral hemisphere. Interestingly,
they observed that intratumoral injection of MSCs was able to
decrease tumor burden and improved the overall survival (OS) of
the animals, either when co-injected with tumor cells or when
transplanted three days post tumor injection [28].
In 2005, Kang et al. performed one of the ﬁrst studies involving
the interaction between MSCs and glioma cells in vitro [58]. Using
rat BM-MSCs, the authors activated these cells with several factors
such as IL2, IL15 and granulocyte macrophage colony stimulating
factor (GM-CSF), or different combinations of the three. Then, the
co-culture of MSCs and 9 L rat glioma cells resulted in increased
cytotoxicity to tumor cells, by a possible increase in apoptosis
mechanisms [58]. Later, the same authors performed similar ex-
periments to test human UCB-MSCs and their effect on glioma
U87 cells [59]. UCB-MSCs were cytotoxic to U87 cells and this effect
was more pronounced when MSCs were activated with IL2, IL15 or
GM-CSF.
In another study, Dasari et al. (2010) showed that human UCB-
MSCs, transplanted one week after tumor inoculation, inhibited
intracranial tumor growth in nude mice (injected with U251 or
5310 glioma cells), upregulating phosphatase and tensin homolog
(PTEN), a tumor suppressor that negatively regulates the PI3K/Akt
signaling pathway, and decreasing the levels of X-linked inhibitor
of apoptosis protein (XIAP) and protein kinase B (Akt) [60]. Similar
ﬁndings were obtained in vitro, with UCB-MSCs inhibiting different
glioma cell lines migration and wound healing capacity [60].
An interesting work from Chien et al. (2011) labeled human BM-
MSCs for in vivo magnetic resonance imaging (MRI) [39]. MSCs
injected two weeks after tumor inoculation (with U87 cells), at the
contralateral brain hemisphere, led to glioma shrinkage as
measured by signal intensity. This was later conﬁrmed by histo-
logical analysis of the tumor tissues [39].
Still in what regards anti-tumoral effects, Ho et al. (2013) saw
that human BM-MSCs inhibited the growth of the glioma cell line
DGli36 and patient-derived gliomas, after direct in vitro co-culture
experiments [61]. This was seen by a reduction of the number of
cells after ﬂow cytometry analysis, in comparison to gliomaPlease cite this article in press as: E.D. Gomes, et al., The impact of Mese
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in vivo subcutaneous co-administration of MSCs and DGli36 cells
into nude mice resulted in signiﬁcant reduction of tumor volume
and vascular density. After in vitro cultures using endothelial pro-
genitor cells (EPCs) or human umbilical vein endothelial cells
(HUVEC) and the MSCs' secretome, it was observed an impaired
capacity of EPCs to form endothelial tubes. Therefore, the authors
hypothesized that BM-MSCs suppress tumor angiogenesis through
the release of anti-angiogenic factors. Moreover, after gene and
protein expression analysis, alterations in PDGF/PDGFR axis seems
to be relevant for the antiangiogenic effects observed [61].
More recently, Pacioni et al. (2017) transplanted human ASCs
and BM-MSCs, either by direct inoculation onto the tumor and
adjacent tissues [orthotopic GBM or Glioma Stem Cells (GSCs) xe-
nografts] or by systemic injections [62]. Intracerebral injection of
ASCs resulted in improved survival of rats with U87 xenografts,
with reduced tumor growth, proliferation and microvascular den-
sity. ASCs and BM-MSCs injected systemically were additionally
capable of homing towards tumor xenografts [62].
However, there are also studies in which MSCs apparently do
not show any effect over gliomas or can even promote tumorigenic
features. Bexell et al. (2009) evaluated the role of transplanted rat
BM-MSCs in experimental gliomas (N29 and N32 glioma cell lines)
[63]. Besides conﬁrming the speciﬁc migration of MSCs to tumors,
the authors showed that intratumoral cellular transplantation one
day after tumor inoculation, did not inﬂuence the survival of
tumor-bearing rats. Interestingly, they suggest that MSCs resem-
bled pericyte-like cells, since they integrated into tumor vessel
walls and expressed pericyte markers such as a-smooth muscle
actin, neuron-glia 2 and PDGF receptor-b [63].
Roger et al. (2012) used a cell line of MSCs, the human marrow
isolated adult multilineage inducible (MIAMI) cells, to target a U87
orthotopic glioma model and no inﬂuence was seen in tumor
growth rate [64]. However, the authors hypothesized that the re-
sults may be glioma-dependent, because MIAMI cells could in fact
induce proliferation of other glioma cell lines in vitro. Moreover, a
subset of MIAMI cells was found to be in a proliferative state in the
U87 tumor microenvironment [64]. A similar effect was seen by
Breznik et al. (2017) [65]. Human BM-MSCs inhibited U87 cells in-
vasion in vitro and in vivo, while on the other hand stimulated U373
invasion capacity. Inherent differences in gene expression, namely
in genes responsible for the response to growth factorsnchymal Stem Cells and their secretome as a treatment for gliomas,
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observed between the two GBM cell lines [65].
The pro- or anti-tumoral effect of MSCs on gliomas might
depend as well on the source of MSCs. Indeed, it is known that the
secretome of MSCs isolated from different sources varies signiﬁ-
cantly [66]. As demonstrated by Akimoto et al. (2013), human UCB-
MSCs and ASCs interactions with gliomas were different [67]. In
in vitro co-cultures, UCB-MSCs inhibited primary GBM tumor cells
growth and caused apoptosis, while ASCs promoted cellular
growth. TRAIL was more expressed in UCB-MSCs, and it is known
its involvement in apoptosis mechanisms [68,69]. In contrast, more
vascularized tumors were formed when ASCs were subcutaneously
co-transplanted with primary glioma cells into mice [67].
Someworks also suggest thatMSCs co-culturedwith tumor cells
might undergo malignant transformation. Liu et al. (2012) have
seen that rat BM-MSCs in indirect cultures with C6 glioma cells
presented decreased wild type p53 and increased expression of
mutant p53 and mdm2 [70]. When transplanted subcutaneously
into immunodeﬁcient-mice, MSCs developed a large tumor at the
injection site within eight weeks. The authors showed that IL6 and
STAT3 signaling were important factors in this mechanism [71].
The in vivo interactions between different glioma cells andMSCs
from various sources are summarized in Table 1. In general, a sub-
stantial part of the studies shows a beneﬁcial effect of MSCs over
glioma-derived tumors. However, some important aspects are
worth to highlight. For instance, similar U87 xenograft mice models
treated with human MSCs presented different outcomes most
likely due to the different source of the MSCs used (BM-MSCs vs
MIAMI cells) [39,64]. Furthermore, in another study [65], different
xenografts (U87 vs U373) in zebraﬁsh embryos had different results
after implantation of the same human BM-MSCs. Finally, in rat
syngeneic glioma models, different rat glioma cell lines (9 L vs N29/
N32) can also impact on the outcome following rat BM-MSCs
application [28,63]. All of these show the importance of the gli-
oma cell line used, its origin (human or rat) and also the source of
MSCs under study.
4. MSCs secretome and gliomas
A relatively small number of studies have focused on the factors
secreted by MSCs and their effects on glioma development and
growth. Being MSCs a population of cells with a high paracrine
signaling component, it is crucial to better understand how this
mechanism could affect gliomas.
In 2014, Ma et al. explored in vitro the molecular mechanisms by
which human UC-MSCs inhibit the growth of C6 glioma cells [72].
Increased levels of dickkopf-1 (DKK1) were observed in UC-MSCs
CM, and the cell inhibitory effect was DKK1-concentration-
dependent. Moreover, the use of anti-DKK1 antibodies attenuated
the inhibition on C6 cells growth. By downregulating or upregu-
lating DKK1, the CM from UC-MSCs lost or gained respectively
abilities to regulate Wnt signaling in C6 cells. In turn, tumor cells
exposed to UC-MSCs CM presented a downregulation in b-catenin
and c-Myc expression [72].
Using the glioma cell line U251 as a model, Yang et al. (2014)
showed that both human ASCs and UC-MSCs CM signiﬁcantly
affected tumor cells' proliferation, migration and invasion [73]. This
was accompanied by an increase in apoptosis (more signiﬁcant
with UC-MSCs CM), together with upregulation of caspase-3 and
caspase-9 and downregulation of antiapoptotic genes, such as
survivin and XIAP. Curiously, a partial differentiation of U251 cells
into astrocyte-like cells (increased GFAP expression) was also
observed after treatment with both MSCs' CM [73].
Relevant work from Kolosa et al. (2015) assessed the effects of
MSCs CM on a particular subset of tumor cells, with stem-likePlease cite this article in press as: E.D. Gomes, et al., The impact of Mese
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BM-MSCs and UC-MSCs were tested on four different GSLC lines.
Cell cycle arrest was induced, with decreased expression of cyclin
D1. The factors secreted by MSCs also induced senescence, dereg-
ulating a total of 13 genes associated with this process, in one of the
GSLC lines. Cell cycle inhibitors p21 and p16, which can trigger
senescence, were upregulated in all four lines after CM exposure.
Increased sensitivity against the chemotherapeutic drug temozo-
lomide was observed, possibly by inducing differentiation of GSLCs
(upregulation of vimentin and GFAP, with concomitant down-
regulation of Sox-2 and Notch-1) [74]. These results could be of the
utmost importance, since these cells are highly resistant to con-
ventional chemo- and radiotherapy regimens, being often respon-
sible for recurrence in gliomas.
In an interesting work, Del Fattore et al. (2015) analyzed the
effect of extracellular vesicles (EVs) secreted by human MSCs
derived from various tissue-sources, on U87 cells [75]. Using 48 h
CM from ASCs, BM-MSCs and UC-MSCs, EVs were isolated and
applied to U87 cultures. It was demonstrated that EVs were inter-
nalized by glioma cells and their effects were different according to
their source. EVs from BM- and UC-MSCs decreased cell prolifera-
tion and induced apoptosis. On the contrary, ASCs-secreted EVs
increased U87 cell proliferation and had no effect on apoptosis.
Curiously, the supernatant of all MSCs CM (containing the secreted
non-vesicular fraction) did not induce any change on glioma cells,
suggesting that the effects observed were speciﬁc to the secreted
EVs, when isolated from the secretome as a whole [75]. EVs are
produced and released by the outer membrane of several types of
cells, including MSCs (MSCs-EVs). These MSCs-EVs are a hetero-
geneous population of vesicles with a diameter of 40e1000 nm that
mainly include exosomes, apoptotic bodies, and microvesicle par-
ticles. Several studies have been describing that MSCs-EVs may
have different effects on tumor growth, metastasis, and drug
response. In fact, some studies demonstrated that these MSCs-EVs
have a tumor-supportive effect, while others showed the opposite
[recently reviewed in Lee et al. (2017) [76] and Zhang et al., 2017
[77]].
Chistyakova and Poljanskaya (2015) tested MSCs from human
fetal tissues, either from fetal bonemarrow or fetal muscle [78]. CM
from both fetal MSCs per se did not inﬂuence the proliferation of
U251 and A172 glioma cells. However, CM collected from co-
cultures of fetal MSCs with U251 cells, led to interesting results:
CM from early time-points of co-culture (3e9 days) stimulated
glioma cells proliferation, while CM obtained from later time-
points (15e21 days) resulted in inhibited cellular proliferation
[78]. This study raised two relevant questions: ﬁrst, it is important
to explore changes in secretome when MSCs are co-cultured with
tumor cells; second, the prolonged co-culture of MSCs with glioma
cells led to a shift from a pro-tumorigenic to a non-tumorigenic CM,
which highlights the importance of further testing the timing of CM
collection.
Another interesting ﬁnding was the contrasting effect observed
by Bajetto et al. (2017) regarding direct cell-cell contact and
secretome-mediated effects [79]. Human UC-MSCs cultured in
direct contact with GBM CSCs inhibited their proliferation, while
the factors secreted by UC-MSCs increased CSCs proliferation rate
through transient ERK1/2 and Akt phosphorylation/activation.
Among those factors IL8, CXCL1, CXCL5 and IL6 were present. In
addition, activation of the CXC chemokine receptor 2 (expressed in
GBM cells) seems to be crucial for the effects observed [79].
A possible explanation could reside on the fact that MSCs
growing in monocultures might secrete a different set of factors
and cytokines, which most likely would be different if they were
pre-conditioned by the presence of tumor cells, either their factors
or the cells themselves. Nevertheless, this study focusses on in vitronchymal Stem Cells and their secretome as a treatment for gliomas,
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Different in vivo models of glioma and treatments with MSCs from various sources.
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effect.
Iser et al. (2016) evaluated whether CM from ASCs (rat origin)
could have an effect on rat C6 glioma cells [80]. Even though cell
viability, cell cycle and growth rate were not altered, there was an
increase in the migratory capacity of C6 cells. Furthermore, CM
treatment led to reduced cell adhesion and changes in their
morphology. At the molecular level, an upregulation of epithelial-
to-mesenchymal transition (EMT)-markers was observed, namely
vimentin, MMP2 and NRAS. EMT is a process often associated to
cancer development and progression. One of the most important
differences of this study is the origin of ASCs, which are from rat
origin. Nevertheless, ASCs CM presented a more pro-tumorigenic
effect, which goes along with Del Fattore and colleagues [75] data
for human ASCs CM.
Also using the secretome of human ASCs, Onzi et al. (2016) [81]
demonstrated that U87 GBM cells presented increased migration,
even though there were no alterations in cell proliferation,
response to temozolomide and sphere-forming capacity.
Our group has also explored the impact of human umbilical cord
perivascular cells (HUCPVCs) secretome on two GBM cell lines,
U251 and SNB-19 [82]. Tumor cells exposed to this secretome
presented signiﬁcantly higher cellular viability, proliferation and
migration in vitro, in comparison to cells exposed to control media.
Moreover, using the in vivo chicken chorioallantoic membrane
(CAM) assay, HUCPVCs CM induced tumor growth and increased
the number of vessels. Molecules such as CCL2, periostin (POSTN)Please cite this article in press as: E.D. Gomes, et al., The impact of Mese
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been described to modulate glioma cells migration and adhesion,
invasion, or even angiogenesis, important hallmarks of glioma
development. However, it is important to notice that, as addressed
before, the secretome of MSCs changes when these cells interact
directly with tumor cell lines. Thus, it would be important in future
studies to further understand how this particular stem cells pop-
ulation interacts with GBM cell lines and their microenvironment.
Overall, the results obtained using MSCs CM in glioma cells are
distinct and variations in protocols might explain these differences.
One important aspect to consider is the use of serum in the media
for CM collection, which seems to be associated with a more pro-
tumorigenic effect, even though there are some exceptions
(Table 2). Nevertheless, the proteins and factors present in each
secretome should be identiﬁed and quantiﬁed in order to better
dissect each secretome effect.
The secretome of MSCs has been characterized by our group and
others [13,83,84], and numerous proteins and small vesicles can be
found. Many of them with potential pro- or anti-tumorigenic ca-
pacity. So far, several signaling molecules secreted by MSCs have
been described to be involved in different biological processes, such
as ECM remodeling, angiogenesis, mitogenic remodeling, apoptosis
inhibition, and tumor aggressiveness, among others [85e87]. MSC-
secreted proteins are capable of coordinating survival, migration,
proliferation, and differentiation responses on healthy tissues and
cancer cells through the activation of many signaling cascades.
Additionally, the secretome of MSCs also presents proangiogenicnchymal Stem Cells and their secretome as a treatment for gliomas,
Table 2
In vitro studies using the secretome of MSCs in different glioma cell lines.
E.D. Gomes et al. / Biochimie xxx (2018) 1e86effects, ECM components and proteins that regulate its composi-
tion. Finally, MSCs secrete a variety of chemoattractant molecules
capable of recruiting diverse cell types, such as immune and pro-
genitor cells (including MSCs themselves).
Besides the ones already mentioned, others such as periostin
[88], semaphorin-7A [89], testican-1 [90] or neuropilin-2 [91] are
also present in MSCs secretome and known to inﬂuence tumor
behavior. A summary of the most common factors present in MSCsFig. 2. Factors secreted by Mesenchymal Stem Cells that have been described as modulators
MSCs secretome.
Please cite this article in press as: E.D. Gomes, et al., The impact of Mese
Biochimie (2018), https://doi.org/10.1016/j.biochi.2018.07.008secretome that can inﬂuence glioma cells is described in Fig. 2.
Further characterization of secretome composition is essential in
order to fully understand the potential beneﬁts or drawbacks of
MSCs application to treat human gliomas.
5. Conclusions
Several factors might explain the differences observed in theof glioma cells behavior. Overall, pro- and anti-tumorigenic factors have been found in
nchymal Stem Cells and their secretome as a treatment for gliomas,
E.D. Gomes et al. / Biochimie xxx (2018) 1e8 7results described so far, in the interaction betweenMSCs and tumor
cells. Variations in protocols are one of the main reasons. Indeed,
different periods of CM collection or different media compositions
(particularly serum percentage) are just some examples. Adding to
this, MSCs' source, and even differences among donors or batches
of isolated cells can inﬂuence the outcome of each experiment. In
what concerns in vivomodels, there is a big variation. Excluding the
differences introduced by cell culturing and animal models, the
mode how the glioma is induced or the timing for MSCs trans-
plantation often differs from study to study. There is also a lack of
in vivo proof-of-concept assays, testing MSCs' secretome effects on
gliomas. Due to its potential of reducing the number of cells needed
to possibly obtain similar ﬁndings, while avoiding problems with
immune rejection, it is necessary to further test this approach.
Overall, MSCs could present an interesting potential as a cancer
treatment strategy, particularly when engineered to deliver anti-
tumor cargos. Their homing ability towards tumor tissues is a
critical feature for their application, however MSCs interactions
with tumor cells still needs to be further explored. Determining the
optimal source for MSCs, the best culture conditions, or even the
most appropriate timing for treatment is essential. In addition, the
development of improved cancermodels, both in vitro and in vivo, is
of the utmost importance to test this. The understanding of this
complex interaction between gliomas and MSCs is a key aspect for
future applications in humans and to improve the prognosis of
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